This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Source: OpenUrlAbstract/FREE Full Text
Investigators from Hamad Medical Corporation, Doha, Qatar, and Providence Health Systems, Renton, WA, conducted a randomized controlled trial to assess the efficacy of palivizumab, a monoclonal antibody to respiratory syncytial virus (RSV), in treating RSV bronchiolitis in hospitalized young infants. Study participants were previously healthy children ≤3 months old with RSV bronchiolitis who presented to the Hamad Pediatric Emergency Center, Doha, Qatar, during 3 bronchiolitis seasons between May 2015 and January 2018 who required inpatient admission. The diagnosis of RSV bronchiolitis was based on a characteristic clinical presentation and a positive rapid RSV antigen test result; need for inpatient admission was based on clinical assessment. Demographic and clinical data were collected, and participants were followed …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.